Skip to main content

Temporomandibular Joint Disorders

1
Pipeline Programs
6
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biomed
BiomedAustralia - Sydney
1 program
1
IbuprofenPhase 1/2Small Molecule1 trial
Active Trials
NCT02602483Completed96Est. Dec 2016
Innovation Pharmaceuticals
1 program
Alloplastic Total Temporomandibular Joint (TMJ) Replacement RegistryN/A1 trial
Active Trials
NCT03991728Recruiting200Est. Dec 2033
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Type D Personality, Somatization and Perceived Social Support in Temporomandibular Joint DisordersN/A1 trial
Active Trials
NCT07292064CompletedEst. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BiomedIbuprofen
City TherapeuticsType D Personality, Somatization and Perceived Social Support in Temporomandibular Joint Disorders
Innovation PharmaceuticalsAlloplastic Total Temporomandibular Joint (TMJ) Replacement Registry

Clinical Trials (3)

Total enrollment: 296 patients across 3 trials

NCT02602483BiomedIbuprofen

Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).

Start: Dec 2015Est. completion: Dec 201696 patients
Phase 1/2Completed
NCT07292064City TherapeuticsType D Personality, Somatization and Perceived Social Support in Temporomandibular Joint Disorders

Type D Personality, Somatization and Perceived Social Support in Temporomandibular Joint Disorders

Start: Feb 2025Est. completion: Jun 2025
N/ACompleted
NCT03991728Innovation PharmaceuticalsAlloplastic Total Temporomandibular Joint (TMJ) Replacement Registry

Alloplastic Total Temporomandibular Joint (TMJ) Replacement Registry

Start: Oct 2019Est. completion: Dec 2033200 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 296 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.